Synthesis and characterization of two known and one new impurities of dolutegravir: In silico evaluation of certain intermediates against SARS CoV-2 O-ribose methyltransferase (OMTase)
- 20 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1271, 133992
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferaseJournal of Biomolecular Structure and Dynamics, 2020
- Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning modelComputational and Structural Biotechnology Journal, 2020
- Identification and Control of Critical Process Impurities: An Improved Process for the Preparation of Dolutegravir SodiumOrganic Process Research & Development, 2016
- Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?Journal of the International AIDS Society, 2016
- Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 ResultsThe Journal of Infectious Diseases, 2013
- New first and second generation inhibitors of human immunodeficiency virus-1 integraseExpert Opinion on Therapeutic Patents, 2011
- HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigationEuropean Journal of Medicinal Chemistry, 2011
- Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected PatientsClinical Infectious Diseases, 2010
- GEMDOCK: A generic evolutionary method for molecular dockingProteins: Structure, Function, and Bioinformatics, 2004
- Pharmaceutical impurities—A mini-reviewAAPS PharmSciTech, 2002